Table 1.
Main demographic, laboratory, and clinical features of 65 patients with SSc.
| Sex | Female | 55 (84.6%) |
| Male | 10 (15.4%) | |
| Race | Caucasian | 63 (96.9%) |
| African | 1 (1.5%) | |
| Sub-Saharan | 1 (1.5%) | |
| Age at diagnosis | 60 (45–67) | |
| Subset | Diffuse SSc | 10 (15.4%) |
| Limited SSc | 55 (84.6%) | |
| Autoantibodies | Anticentromere | 42 (64.6%) |
| Anti-topoisomerase I (topo I) a | 10 (15.4%) | |
| Anti-RNA polymerase III (RNAP3) a | 4/60 (6.7%) | |
| Anti-Th/To | 1/60 (1.7%) | |
| Anti-PM/Scl | 1/60 (1.7%) | |
| Main clinical features | Interstitial lung disease | 12 (18.5%) |
| Group 1 pulmonary arterial hypertension | 11 (16.9%) | |
| Renal crisis | 4 (6.2%) |
SSc: systemic sclerosis.
a
One patient was positive both for anti-topo I and RNAP3.